Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

Clinical trial NCT07147426 · RECRUITING

Trial details

NCT number: NCT07147426
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head &Amp; Neck Squamous Cell Carcinoma

Start date: 2025-10-01
Primary completion: 2027-10-20
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.